Literature DB >> 31212115

Role of diabetes and insulin use in the risk of stroke and acute myocardial infarction in patients with atrial fibrillation: A Medicare analysis.

Amgad Mentias1, Ghanshyam Shantha2, Oluwaseun Adeola1, Geoffrey D Barnes3, Bharat Narasimhan4, Konstantinos C Siontis2, Deborah A Levine5, Rajan Sah1, Michael C Giudici1, Mary Vaughan Sarrazin6.   

Abstract

BACKGROUND: Atrial fibrillation (AF) is associated with elevated risk for ischemic stroke and myocardial infarction (MI). The aim of the study is to assess the role of insulin use on the risk of stroke and MI in AF patients with diabetes.
METHODS: We identified Medicare beneficiaries with new AF in 2011 to 2013. Primary outcomes were ischemic stroke and MI. Multivariate Cox regression models were used to assess the association between AF and time to stroke and MI. We adjusted for anticoagulant as a time-dependent covariate.
RESULTS: Out of 798,592 AF patients, 53,212 (6.7%) were insulin-requiring diabetics (IRD), 250,214 (31.3%) were non-insulin requiring diabetics (NIRD) and 495,166 (62%) were non-diabetics (ND). IRD had a higher risk of stroke when compared to NIRD (adjusted HR: 1.15, 95% CI 1.10-1.21) and ND (aHR 1.24, 95% CI 1.18-1.31) (P < .01 for both). The risk of stroke was higher in NIRD compared to ND (aHR 1.08, 95% CI 1.05-1.12). For the outcome of MI, IRD had a higher risk compared to NIRD (aHR 1.24, 95% CI 1.18-1.31) and ND (aHR 1.46, 95% CI 1.38-1.54)]. NIRD had a higher risk compared to ND (aHR 1.17, 95% CI 1.13-1.22). Anticoagulation were most effective at preventing stroke in ND [0.72 (0.69-0.75)], and NIRD [0.88 (0.85-0.92)], but were not associated with significant reduction in stroke in IRD [0.96 (0.89-1.04)].
CONCLUSION: There is an incremental risk of ischemic stroke and MI from non-diabetics to non-insulin diabetics with the highest risk in insulin users. Protective effect of anticoagulation is attenuated with insulin use. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31212115      PMCID: PMC6639137          DOI: 10.1016/j.ahj.2019.05.003

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  33 in total

1.  Abnormal markers of endothelial cell activation and oxidative stress in children, adolescents and young adults with type 1 diabetes with no clinical vascular disease.

Authors:  T A Elhadd; G Kennedy; A Hill; M McLaren; R W Newton; S A Greene; J J Belch
Journal:  Diabetes Metab Res Rev       Date:  1999 Nov-Dec       Impact factor: 4.876

2.  Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

Authors:  Steven P Marso; Stephen C Bain; Agostino Consoli; Freddy G Eliaschewitz; Esteban Jódar; Lawrence A Leiter; Ildiko Lingvay; Julio Rosenstock; Jochen Seufert; Mark L Warren; Vincent Woo; Oluf Hansen; Anders G Holst; Jonas Pettersson; Tina Vilsbøll
Journal:  N Engl J Med       Date:  2016-09-15       Impact factor: 91.245

3.  Inflammation and hemostasis in atrial fibrillation and coronary heart disease: The REasons for Geographic And Racial Differences in Stroke study.

Authors:  Wesley T O'Neal; Elsayed Z Soliman; George Howard; Virginia J Howard; Monika M Safford; Mary Cushman; Neil A Zakai
Journal:  Atherosclerosis       Date:  2015-09-08       Impact factor: 5.162

4.  Cellular and molecular mechanisms of vascular injury in diabetes--part I: pathways of vascular disease in diabetes.

Authors:  Rosalinda Madonna; Raffaele De Caterina
Journal:  Vascul Pharmacol       Date:  2011-03-29       Impact factor: 5.773

5.  Plasma von Willebrand factor and soluble p-selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors.

Authors:  Dwayne S G Conway; Lesly A Pearce; Bernard S P Chin; Robert G Hart; Gregory Y H Lip
Journal:  Circulation       Date:  2002-10-08       Impact factor: 29.690

6.  Elevated concentrations of circulating adhesion molecules and their association with microvascular complications in insulin-dependent diabetes mellitus.

Authors:  P Fasching; M Veitl; M Rohac; C Streli; B Schneider; W Waldhäusl; O F Wagner
Journal:  J Clin Endocrinol Metab       Date:  1996-12       Impact factor: 5.958

7.  Hemostasis variables in type I diabetic patients without demonstrable vascular complications.

Authors:  C el Khawand; J Jamart; J Donckier; B Chatelain; E Lavenne; M Moriau; M Buysschaert
Journal:  Diabetes Care       Date:  1993-08       Impact factor: 19.112

8.  Coagulation and fibrinolytic system impairment in insulin dependent diabetes mellitus.

Authors:  F Carmassi; M Morale; R Puccetti; F De Negri; F Monzani; R Navalesi; G Mariani
Journal:  Thromb Res       Date:  1992-09-15       Impact factor: 3.944

9.  Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?

Authors:  Alan S Go; Elaine M Hylek; Yuchiao Chang; Kathleen A Phillips; Lori E Henault; Angela M Capra; Nancy G Jensvold; Joe V Selby; Daniel E Singer
Journal:  JAMA       Date:  2003-11-26       Impact factor: 56.272

10.  Insulin-Requiring Versus Noninsulin-Requiring Diabetes and Thromboembolic Risk in Patients With Atrial Fibrillation: PREFER in AF.

Authors:  Giuseppe Patti; Markus Lucerna; Ilaria Cavallari; Elisabetta Ricottini; Giulia Renda; Ladislav Pecen; Fabio Romeo; Jean-Yves Le Heuzey; Josè Luis Zamorano; Paulus Kirchhof; Raffaele De Caterina
Journal:  J Am Coll Cardiol       Date:  2017-01-31       Impact factor: 24.094

View more
  5 in total

1.  Comparative Effectiveness of Rivaroxaban, Apixaban, and Warfarin in Atrial Fibrillation Patients With Polypharmacy.

Authors:  Amgad Mentias; Eric Heller; Mary Vaughan Sarrazin
Journal:  Stroke       Date:  2020-06-10       Impact factor: 7.914

2.  Association of Diabetes Duration and Glycemic Control With Stroke Rate in Patients With Atrial Fibrillation and Diabetes: A Population-Based Cohort Study.

Authors:  Husam Abdel-Qadir; Madison Gunn; Iliana C Lega; Andrea Pang; Peter C Austin; Sheldon M Singh; Cynthia A Jackevicius; Karen Tu; Paul Dorian; Douglas S Lee; Dennis T Ko
Journal:  J Am Heart Assoc       Date:  2022-02-08       Impact factor: 6.106

Review 3.  Association of Antihyperglycemic Therapy with Risk of Atrial Fibrillation and Stroke in Diabetic Patients.

Authors:  Cristina-Mihaela Lăcătușu; Elena-Daniela Grigorescu; Cristian Stătescu; Radu Andy Sascău; Alina Onofriescu; Bogdan-Mircea Mihai
Journal:  Medicina (Kaunas)       Date:  2019-09-15       Impact factor: 2.430

Review 4.  Type 2 Diabetes, Atrial Fibrillation, and Direct Oral Anticoagulation.

Authors:  Dana Prídavková; Matej Samoš; Tomáš Bolek; Ingrid Škorňová; Jana Žolková; Peter Kubisz; Ján Staško; Marián Mokáň
Journal:  J Diabetes Res       Date:  2019-12-06       Impact factor: 4.011

5.  Pharmacotherapy for diabetes and stroke risk: Results from ROCKET AF.

Authors:  Francis E Ugowe; Anne S Hellkamp; Allen Wang; Richard C Becker; Scott D Berkowitz; Günter Breithardt; Keith A A Fox; Jonathan L Halperin; Graeme J Hankey; Kenneth W Mahaffey; Christopher C Nessel; Daniel E Singer; Manesh R Patel; Jonathan P Piccini
Journal:  Heart Rhythm O2       Date:  2021-04-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.